Introduction. The incidence of COVID-19 continues to rise rapidly worldwide, leading to significant socio-economic damage to health and economic systems.Objective. To determine the effectiveness of intravenous immunoglobulin G (IVIG) in combination with a basic therapy in severe COVID-19.Materials and methods. A retrospective cohort study of 8 case histories of patients with severe COVID-19 for the period from 27.08.2020 to 20.03.2021 was conducted in the intensive care unit (ICU) of the infectious diseases department of the Municipal Non-Profit Enterprise «Kyiv City Clinical Hospital №17» (MNE KCCH №17).Results and discussions. During the period from 27.08.20 to 20.03.21 in the intensive care unit (ICU) of the infectious department of the Municipal Non-Profit Enterprise «Kyiv City Clinical Hospital №17» (MNE KCCH №17) there were 163 patients, of whom 79 died and the mortality rate was 48.4%. The mean age of patients was 63.5 ± 12.9 years (19 to 95 years). The mean age of death was 66.9 ± 9.9 years (40 to 87 years).During the study period, 8 patients received IVIG (5%) together with a basic therapy. The mean age of patients was 51.4 ± 14.7 years (from 29 to 69 years). Mortality among patients receiving IVIG was 37.5%.Conclusions. Mortality of patients who received IVIG in addition to a basic therapy was significantly lower compared to patients who received only basic therapy, 37.5% and 48.4%, respectively.

Introduction. Most hospitalized patients with COVID-19, both in medical institutions in Ukraine and in other countries, are unreasonably receiving antibacterial drugs, despite the fact that secondary bacterial infections in patients with COVID-19 are extremely rare, as evi-denced by numerous scientific studies (from 3 up to 10% among hospitalized patients).The goal of the work. Conduct a retrospective analysis of the frequency of use and justification of the prescription of antibacterial drugs in hospitalized patients with COVID-19 in two medical institutions in the city of Kyiv.Materials and methods. A retrospective study of 240 medical records of an inpatient (form 003 / y), randomly selected, hospitalized with a diagnosis of COVID-19 from September 2020 to April 2021, who were hospitalized in two communal medical institutions in the city of Kyiv.Results and discussion. The number of patients who received antibacterial drugs in the CUE KCCH №17 (antibacterial drugs were prescribed by concilium and only if there was a reasonable suspicion or confirmation of a bacterial infection) was 20 out of 120 (16.7%), while in the compared institution the frequency of prescription of antibacterial drugs accounted for 117 patients out of 120 analyzed cases (97.5%). The average length of stay of a patient on inpatient treatment in the two compared institutions had no statistically significant differences and was 11.2 ± 6.0 days in patients with the CUE KCCH №17, and 12.3 ± 4.6 days in patients from the control institution (р>0.05). The mortality rate did not differ between patients treated in both hospitals.Conclusions. After analyzing the results of the study, it can be concluded that the routine prescription of antibacterial drugs without available indications does not have the advantage of improving the quality of treatment for patients with COVID-19, does not reduce the duration of inpatient treatment and the mortality rate, does not prevent the risk of secondary bacterial infection in hospitalized patients. however, it leads to a significant increase in the cost of treating a case of the disease and leads to an increase in the resistance of hospital microorganisms to antibacterial drugs.